We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A First-in-human Study of the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR439459 Monotherapy and Combination of SAR439459 and Cemiplimab in Patients With Advanced Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03192345
Recruitment Status : Terminated (Occurrence of objective responses in multiple indications in the Phase 1b was not enough to warrant further exploration in view of competitive landscape and some toxicity (mostly bleeding events).)
First Posted : June 20, 2017
Last Update Posted : May 12, 2022
Sponsor:
Information provided by (Responsible Party):
Sanofi